2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. 5 alpha Reductase

5 alpha Reductase

5α-reductase

5 alpha Reductase

Related Products

PDF 0.22 MB

Steroid 5-α reductase (5AR) is a membrane-bound protein that is responsible for reducing steroids such as testosterone, progesterone, and androstenedione to 5-α reduced metabolites such as 5-α dihydrotestosterone (DHT), 5-α dihydroprogesterone and androstanedione, respectively. There are three isoforms of 5AR in humans: SRD5A1, SRD5A2, and SRD5A3. SRD5A1 and SRD5A2 have functionality for 5-α reduction of steroids in humans. DHT is a more potent androgen than testosterone and has a function in androgen receptor activation.

The inactivating mutations in 5αR2 lead to disorders of sexual development. The regulation of 5AR is important for the treatment of benign prostate hyperplasia (BPH) and prostate cancer (PC), and 5AR inhibitors are widely used for the treatment of androgen-dependent benign or malignant prostatic diseases.

5 alpha Reductase Related Products (49):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-106614
    Osaterone acetate
    		Inhibitor
    Osaterone acetate is an orally active steroid anti-androgen agent, mainly used for benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate competitively antagonizes androgen receptor and inhibits 5α-reductase, reducing the concentration of dihydrotestosterone (DHT) while blocking the growth-stimulating effects of testosterone and DHT on prostate cells. Osaterone acetate can rapidly alleviate the symptoms of BPH in dogs without affecting the fertility of breeding dogs.
    Osaterone acetate
  • HY-133949
    8,11-Eicosadiynoic acid
    		Inhibitor
    8,11-Eicosadiynoic acid, an unsaturated fatty acid, is a steroid 5α-reductase inhibitor. 8,11-Eicosadiynoic acid can be used for the research of acne.
    8,11-Eicosadiynoic acid
  • HY-118091A
    Bexlosteride
    		Inhibitor
    Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer.
    Bexlosteride
  • HY-13613S2
    Dutasteride-13C,15N,d
    		Inhibitor
    Dutasteride-13C,15N,d is 15N and deuterated labeled Dutasteride (HY-13613). Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT.
    Dutasteride-<sup>13</sup>C,<sup>15</sup>N,d
  • HY-13635R
    Finasteride (Standard)
    		Inhibitor
    Finasteride (Standard) is the analytical standard of Finasteride. This product is intended for research and analytical applications. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.
    Finasteride (Standard)
  • HY-19292
    AS-601811
    		Inhibitor
    AS-601811(compound 47) is a 5alpha-reductase 1 inhibitor with the IC50 of 20 nM and can be used for study of alopecia and hirsutism.
    AS-601811
  • HY-19144
    ONO-3805
    		Inhibitor
    ONO-3805 is an early lead compound of a non-steroidal 5α-reductase inhibitor, used to inhibit the conversion of testosterone to dihydrotestosterone, with potential effects in inhibiting benign prostatic hyperplasia.
    ONO-3805
  • HY-118091
    LY191704
    		Inhibitor
    LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by 5α-reductase type 1.
    LY191704
  • HY-165478
    FCE 28260
    		Inhibitor
    FCE 28260 is an orally active 4-azacyclic 5α-reductase (5αR) inhibitor. FCE 28260 exhibits IC₅₀ values for human 5αR type 1 and 5αR type 2 of 36 and 3.3 nM, respectively, and for human and rat prostates with IC₅₀ values of 16 and 15 nM, respectively. FCE 28260 simultaneously blocks the production of dihydrotestosterone (DHT) in the prostate and peripheral tissues. FCE 28260 can significantly inhibit the induction of prostatic and seminal vesicle hyperplasia by testosterone (T) in rat models, without inhibiting the growth of the prostate in DHT implantation models. FCE 28260 can be used for the studies DHT-dependent diseases such as benign prostatic hyperplasia (BPH).
    FCE 28260
  • HY-121700
    L-751788
    		Inhibitor
    L-751788 is a selective inhibitor of type I of 5α-reductase. L-751788 does not have a significant impact on the differentiation of the external genitalia in animals. When administered orally to pregnant rhesus monkeys, L-751788 (2, 10 mg/kg) did not cause abnormalities in fetal external genitalia.
    L-751788
  • HY-13635A
    Finasteride acetate
    		Inhibitor
    Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.
    Finasteride acetate
  • HY-B1734
    16-Dehydropregnenolone acetate
    		Inhibitor
    16-Dehydropregnenolone acetate (16-DPA), a sterols compound, is an orally active 17α-hydroxylase and 5α-reductase inhibitor. 16-Dehydropregnenolone is also a potent bile acid receptor (BAR)/farnesoid X receptor (FXR) antagonist. 16-Dehydropregnenolone hypolipidemic and anticancer effects. 16-Dehydropregnenolone acetate (16-DPA) is the drug intermediate that can be used for synthesis of Dexamethasone (HY-14648) and related other steroidal pharmacophores.
    16-Dehydropregnenolone acetate
  • HY-N13195
    (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one
    		Inhibitor
    (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one shows a 5a-reductase inhibitory activity with an IC50 value of 41.9 μM. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one inhibits the growth of the ventral prostate induced by testosterone in rat. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one is promising for research of benign prostatic hyperplasia (BPH) as well as other 5α-dihydrotestosterone (DHT)-related disorders, such as acne and male pattern baldness.
    (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one
  • HY-175719
    SRD5A1-IN-2
    		Inhibitor
    SRD5A1-IN-2 is a inhibitor of steroid 5α-reductase type-1 (SRD5A1), with an IC50 of 8.5 μM. SRD5A1-IN-2 downregulates SRD5A1 protein expression in HaCaT cells. SRD5A1-IN-2 reduces dihydrotestosterone (DHT) production in HaCaT cells. SRD5A1-IN-2 can be used for the study of androgen-related conditions such as androgenetic alopecia (AGA).
    SRD5A1-IN-2
  • HY-105217
    Turosteride
    		Inhibitor
    Turosteride is a selective 5 alpha-reductase inhibitor, with IC50 values of 55 and 53 nM for human and rat prostatic 5 alpha-reductases, respectively. Turosteride can reduce the prostate and seminal vesicle weights.
    Turosteride
  • HY-123323
    MK-0434
    		Inhibitor
    MK-0434 is an orally active steroid 5α-reductase inhibitor. MK-0434 specifically inhibits steroid 5α-reductase, thereby reducing the level of dihydrotestosterone (DHT) in the body. MK-0434 can be used in the study of benign prostatic hyperplasia.
    MK-0434
  • HY-107385R
    Epristeride (Standard)
    		Inhibitor
    Epristeride (Standard) is the analytical standard of Epristeride. This product is intended for research and analytical applications. Epristeride (ONO-9302) is a selective, specific and orally active uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Epristeride has inhibitory effects for SR isoenzymes types 2 with Ki value of 0.7-2 nM. Epristeride can be used for the research of prostatic hyperplasia and acne.
    Epristeride (Standard)
  • HY-106363
    MK-0963
    		Inhibitor
    MK-0963 is a steroidal 5α-reductase inhibitor. MK-0963 reduces serum dihydrotestosterone (DHT) concentrations in a dose-dependent manner. MK-0963 can be used for the study of dihydrotestosterone-related diseases such as benign prostate hyperplasia (BPH).
    MK-0963
  • HY-19284
    FR-146687
    		Inhibitor
    FR-146687 (FK 687) is a selective and orally active 5α-reductase inhibitor with IC50s of 1.7 nM and 4.6 nM for rat and human 5α-reductases, respectively. FR-146687 shows no inhibitory effects on other steroid oxidoreductases.
    FR-146687
  • HY-108952R
    17,17-(Ethylenedioxy)androst-4-en-3-one (Standard)
    		Inhibitor
    17,17-(Ethylenedioxy)androst-4-en-3-one (Standard) is the analytical standard of 17,17-(Ethylenedioxy)androst-4-en-3-one (HY-108952). This product is intended for research and analytical applications. 17,17-(Ethylenedioxy)androst-4-en-3-one (4- androstene- 3, 17- dione- 17- cyclic ethylene ketal) is an effective ingredient in cosmetics, which can be used for acne and promote hair growth research. 17,17-(Ethylenedioxy)androst-4-en-3-one can inhibit the reductase activity and inhibit the bond of a receptor protein and 5α-DHT.
    17,17-(Ethylenedioxy)androst-4-en-3-one (Standard)